EGFR and non-small cell lung carcinoma: The effect of the EGFR-tyrosine kinase inhibitor, gefitinib, at suboptimal doses was reported to be potentiated in the presence of SREBP1 inhibitors such as betulin and fatostatin in models of non-small cell lung cancer [53].